Status: Recruiting
Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea
This surveillance is to investigate the safety profile of MenQuadfi®, when administered to participants aged 6 weeks to 55 years under the real-world clinical practice settings as per approved indications, including the Adverse Drug Reactions (ADRs)\*. \*It includes ADRs that were not fully recognized in clinical practice, or unexpected ADRs which refer to those not listed in the approved drug labeling.
Participants needed: 706
Trial details
Age: 6-55Biological sex: AllType: ObservationalSponsor: SanofiUpdated: Jul 29, 2026Locations: 9
Eligibility criteria
Aged 6 weeks to 55 years on the day of MenQuadfi® vaccination [+2]
Participating or planning participation in any other clinical studies investigat... [+2]